RCM
DMAQR

Radcliffe Capital Management’s Deep Medicine Acquisition Corp. Rights DMAQR Stock Holding History

Radcliffe Capital Management’s Portfolio DMAQR Stock Details DMAQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-70,000
Closed -$11.9K – 512
2023
Q2 		$11.9K Hold
70,000
– – ﹤0.01% 393
2023
Q1 		$8.81K Buy
+70,000
New +$7.09K ﹤0.01% 564

Other funds holding DMAQR

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

Radcliffe Capital Management's DMAQR Position: Q3 2023 in Review

Radcliffe Capital Management sold out of Deep Medicine Acquisition Corp. Rights (DMAQR) in Q3 2023, closing a stake of 70,000 shares — an estimated $11.9K sold.

Radcliffe Capital Management first reported a position in DMAQR in Q1 2023 and held it in 2 quarters. The position peaked at $11.9K in Q2 2023. 26 funds tracked by Wall St. Rank hold DMAQR as of Q3 2023.

  • Radcliffe Capital Management reported no remaining Deep Medicine Acquisition Corp. Rights position as of Q3 2023 after selling out during the quarter.
  • Radcliffe Capital Management sold 70,000 Deep Medicine Acquisition Corp. Rights shares in Q3 2023, an estimated $11.9K.
  • Radcliffe Capital Management first reported a position in Deep Medicine Acquisition Corp. Rights in Q1 2023 and held it in 2 quarters.
  • Radcliffe Capital Management's Deep Medicine Acquisition Corp. Rights position peaked at $11.9K in Q2 2023.
  • 26 funds tracked by Wall St. Rank held Deep Medicine Acquisition Corp. Rights as of Q3 2023.

Based on Radcliffe Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.